Navigation Links
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Date:8/31/2009

nt (SPA), pending commencement. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including KRX-0401 and Zerenex; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
2. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
3. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
4. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Dallas-based TopMD™ Skin Care today announced results of ... of their flagship product, CLn® BodyWash for ... in the May/June 2013 issue of Pediatric Dermatology ... Cleanser Shows Clinical Response and Excellent Acceptability in the ... consistent use of the product by 18 pediatric patients ...
(Date:5/21/2013)... Dimensional Insight, a developer of business intelligence ... Health System, a 275-bed hospital based in Cumberland, ... help it analyze its data more quickly. Western Maryland ... through Dimensional Insight’s recently announced partnership with Premier ... has massive amounts of data in disparate systems, such ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Romio ... people with trusted services & businesses, announced today that ... Emergency Medical Care. , Emergency Medical Care is located ... services 24 hours a day. The guarantee of ... is a promising resource for the neighborhood and a ...
(Date:5/21/2013)... Reporter , , MONDAY, May 20 (HealthDay News) -- Young ... a higher risk of getting into car crashes, but ... missed sleep on weekends puts them in even greater ... is another challenge to adolescents that comes with lack ... founder of the Center for Injury Research and Prevention ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Racial disparities exist ... hospitals in the United States, according to a large ... undergo surgery as part of their initial treatment, researchers ... whites to have surgery in the early stages of ... for stage 1 and stage 2 disease than white ...
Breaking Medicine News(10 mins):Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 2Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 3Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Romio Announces Mini Video Series Featuring Local Business Emergency Medical Care 2Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... NY) For the third time in four months, the ... National Institutes of Health (NIH) has awarded Albert Einstein College ... helping people infected with multidrug-resistant tuberculosis (MDR-TB). Taken ... latest awardee Neel Gandhi, M.D. , assistant professor ...
... July 27, 2010 Researchers at UT Southwestern Medical ... doses of corticosteroids given repeatedly over several weeks may ... affects more than 1 million people in the U.S. ... sometimes use illegally to bulk up muscle, corticosteroids are ...
... By Madonna Behen HealthDay Reporter , MONDAY, July ... Administration has required that all epilepsy drugs bear a warning ... doctors report that only certain medications may increase the risk ... the findings and say the paper raises more questions than ...
... such as everolimus that target the protein mTOR are used ... respond to the treatment. A team of researchers, led by ... has now identified a way to help predict which patients ... that human cancer cells with mutations in the PIK3CA gene ...
... major research company affiliated with the University of Colorado ... the University of Colorado,s Anschutz Medical Campus to more ... laboratory to the patient. CPC, formally known as the ... Incorporated building across the street from the campus on ...
... Society for Radiation Oncology (ASTRO) has named N. Reed ... diagnostic radiology, as its 2010 Honorary Member, which is ... researchers and leaders in disciplines other than radiation oncology, ... with this honor during the Awards Ceremony at ASTRO,s ...
Cached Medicine News:Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Researchers uncover biological rationale for why intensive lupus treatment works 2Health News:Researchers uncover biological rationale for why intensive lupus treatment works 3Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 2Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 3Health News:University of Colorado joins forces with major research affiliate 2Health News:ASTRO names radiologist, ABR president Society's 2010 Honorary Member 2
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Regulatory and Reimbursement Scenario for Medical Devices ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   Changing ... in the US Market   ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2
... Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today ... that once-daily Victoza ® in combination with metformin produced sustained and significantly ... ® plus metformin at 52 weeks. , ... Key findings from the study include: , ...
... JACKSONVILLE, Fla. , June 28 ... of its SurgiSteer™ laparoscopic instruments.  Developed from licensed ... will exploit single port laparoscopic surgery with its ... and Endo Scissors, available in both free and ...
Cached Medicine Technology:New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 2New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 3New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 4New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 5New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 6New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 7Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments 2
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
Medicine Products: